Literature DB >> 26096279

Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing.

Ching-Li Tseng1, Jerard Seghatchian2, Thierry Burnouf3.   

Abstract

There is much interest in the clinical use of serum-converted human blood or platelet concentrates in regenerative medicine, most specifically for wound healing and tissue repair of soft and hard tissues. The scientific rationale supporting the clinical efficacy of these preparations is based on the expectation that their physiological mixture of natural growth factors can orchestrate cell expansion and differentiation in vivo. However, a lack of standardization and regulatory oversight of these blood materials maintain a perception of uncertainty in the scientific and medical community on the value of these preparations for some clinical indications. More studies are needed to understand the mechanism of action underlying their expected efficacy and standardize their use, and benefit from their biological versatility. One application of serum is as eye drop for treating dry eye syndrome (DES), a multifactorial disease of the ocular surface, which has a prevalence of 15% of more in the population. DES can lead to chronic inflammation of the ocular surface, surface impairment in the cornea and conjunctiva, and, in patients with Sjogren syndrome, result in a disruption of the ocular surface epithelium. Objective experimental assessment of safety and efficacy of serum eye drops can help establish scientific rationale in optimal product composition and use. This can be achieved, first, through cell cultures with relevant cell models, before considering, then, animal studies using DES animal models. Several models have been evaluated and are reported in this concise review. The model we have developed encompasses the use of rabbits, where their eyes are treated with 0.1% benzalkonium chloride (BAC), a common preservative in ophthalmic agents, 3 times daily for 4 weeks. This relatively mild treatment results in moderate DES pathology, with a stable shortage of tear secretion throughout a 7-week study period, which we found suitable for assessing efficacy of serum eye drops.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26096279     DOI: 10.1016/j.transci.2015.05.016

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  6 in total

1.  Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome.

Authors:  Ching-Li Tseng; Zhi-Yu Chen; Ting-Yi Renn; Shun-Hung Hsiao; Thierry Burnouf
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

2.  The Effect of Dry Eye Disease on Scar Formation in Rabbit Glaucoma Filtration Surgery.

Authors:  Hong Ji; Yingting Zhu; Yingying Zhang; Yu Jia; Yiqing Li; Jian Ge; Yehong Zhuo
Journal:  Int J Mol Sci       Date:  2017-05-28       Impact factor: 5.923

3.  A Comparison of the Effects of Benzalkonium Chloride on Ocular Surfaces between C57BL/6 and BALB/c Mice.

Authors:  Qian Yang; Yafang Zhang; Xiuping Liu; Nan Wang; Zhenyu Song; Kaili Wu
Journal:  Int J Mol Sci       Date:  2017-02-26       Impact factor: 5.923

Review 4.  Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products.

Authors:  Victor J Drew; Ching-Li Tseng; Jerard Seghatchian; Thierry Burnouf
Journal:  Front Med (Lausanne)       Date:  2018-02-23

5.  TEMPO-Oxidized Sacchachitin Nanofibers (TOSCNFs) Combined with Platelet-Rich Plasma (PRP) for Management of Dry Eye Syndrome.

Authors:  Hong-Liang Lin; Ting-Huan Wu; Hsiu-O Ho; Fang-Ching Chao; Meng-Huang Wu; Der-Zen Liu; Ling-Chun Chen; Ming-Thau Sheu
Journal:  Int J Nanomedicine       Date:  2020-03-12

6.  Synergistic Effect of Artificial Tears Containing Epigallocatechin Gallate and Hyaluronic Acid for the Treatment of Rabbits with Dry Eye Syndrome.

Authors:  Ching-Li Tseng; Ya-Jung Hung; Zhi-Yu Chen; Hsu-Wei Fang; Ko-Hua Chen
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.